alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,626–1,650 of 3,821 studies published 2025 (page 66 of 153) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

NIA perspective on harmonizing International Health and Retirement Studies (HRS) and Harmonized Cognitive Assessment Protocol (HCAP) studies

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journals of Gerontology Series B 2025-12-13

The NIA hopes to see continued collection and harmonization of the International HRS and HCAP data, as well as continued use of the data to advance our knowledge of how behavioral and social factors influence aging and life course outcomes, including those related to AD/ADRD. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A vision transformer approach for fully automated and scalable dementia screening using clock drawing test images

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-07-01

The ViT approach predicted dementia with 76.5% balanced accuracy, outperforming human-scored features (74.3%) and existing deep learning models (MiniVGG = 73.3%, MobileNetV2 = 72.3%, relevance factor variational autoencoder = 69.1%) on the TDRA dataset. 3 key findings →

Participants: 862 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Enlarged perivascular spaces correlate with blood-brain barrier leakage and cognitive impairment in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Alzheimer s Disease 2025-02-09

BackgroundThe clinical significance of enlarged perivascular spaces (EPVS) in Alzheimer' s disease (AD) was ambiguous. 2 key findings →

Participants: 64 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Trajectories of CSF and plasma MTBR‐tau 243 and phosphorylated‐tau species across the Alzheimer's disease continuum

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-12-01

The CSF and plasma cohorts were on average 71.4(±8.5) and 72.2 (±9.3) years of age, 49.1%/50.8% was female, and 263/453 (0.59%/51.8%) were cognitively impaired, respectively. 4 key findings →

Participants: 97 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cholinergic basal forebrain atrophy accelerates cognitive decline via cortical thinning: The moderating role of amyloid-β pathology in preclinical Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 45 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-07-29

Progressive cortical thinning in multiple cognition-related regions was significantly associated with cBF atrophy. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Multidisciplinary Home-Based Palliative Care for People Living with Dementia: Preliminary Findings on Palliative Care Concerns and Caregiver Burden

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Journal of Applied Gerontology 2025-05-22

We describe the complex care needs faced by families in dementia care and specialized multidisciplinary palliative care delivered through home visits as a feasible way to support advancing stages of dementia. 1 key finding →

Design: longitudinal study Participants: 27 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Exploring the Immediate and Long-Term Effects of Immersive Virtual Reality on Behavioral and Psychological Symptoms of Dementia and Caregiver Burden: Longitudinal Observational Study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. JMIR Serious Games 2025-07-16

Significant improvements were observed after 1 month of VR intervention in both caregiver burden (Z=-3.095, P=.002, r=0.34) and neuropsychiatric symptoms (Z=-2.929, P=.003, r=0.32). 5 key findings →

Design: longitudinal study Participants: 82 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Equity of access in rural and metropolitan dementia diagnosis, management, and care experiences: an exploratory qualitative study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. International Journal for Equity in Health 2025-03-16

Participants were distributed across various regions of Australia: seven interviews from inner regional Australia, five interviews from outer regional Australia, and twenty-one interviews from metropolitan areas. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Service delivery and the role of clinical pharmacists in UK primary care for older people, including people with dementia: a scoping review

✓ Peer-reviewed alzhub usefulness score 45 out of 100. BMC Family Practice 2025-01-14

A total of 30 articles were included. These detail the multifaceted responsibilities of clinical pharmacists in primary care for older people. 5 key findings →

Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Associations between Ultrafine Particles and Incident Dementia in Older Adults

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Environmental Science & Technology 2025-03-13

High Resolution Image Download MS PowerPoint Slide Fine particulate matter (PM 2.5 ) is linked to dementia risk, but ultrafine particles (UFPs, <100 nm) may be even more toxic due to their distinct physicochemical properties. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuroimaging markers of dementia across race/ethnicity and sex/gender using an intersectional approach within the HABS‐HD cohort

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-09-01

We analyzed data from 3433 dementia-free participants with either magnetic resonance imaging or positron emission tomography (PET) data at baseline (mean [standard deviation] age: 65 [9] years, 36% non-Hispanic White [NHW], 27% Black, 37% Hispanic, and 63% women). 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Enhancing participation of historically minoritized groups in Alzheimer disease and related dementias research: National Conference Report

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer s & Dementia 2025-05-01

This paper reports on a Conference organized by the Washington University School of Medicine's (WUSM) Knight Alzheimer Disease Research Center (Knight ADRC), entitled "Enhancing Participation by Minoritized Groups in Alzheimer Disease and Related Dementia (ADRD) Research." 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Use of sodium‐glucose cotransporter‐2 inhibitors and risk of dementia: A population‐based cohort study

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Diabetes Obesity and Metabolism 2025-02-10

The final cohort included 47 335 new users of DPP-4i or SGLT-2i. In the primary analysis, the incidence of dementia was 500.2 and 347.5 per 100 000 person-years in users of DPP-4i and SGLT-2i, respectively. 5 key findings →

Participants: 47 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Artificial Intelligence in the Diagnostic Use of Transcranial Doppler and Sonography: A Scoping Review of Current Applications and Future Directions

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Bioengineering 2025-06-21

Artificial intelligence (AI) is revolutionizing the field of medical imaging, offering unprecedented capabilities in data analysis, image interpretation, and decision support. 2 key findings →

Participants: 41 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed